Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.
Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.
Candel Therapeutics, Inc. (Nasdaq: CADL) has secured a $25 million loan from Silicon Valley Bank, with $20 million available immediately and up to $5 million contingent on specific milestones. This financing extends the company's cash runway into Q4 2023, providing operational flexibility ahead of key clinical trials, including CAN-2409 and CAN-3110. CEO Paul Peter Tak highlights the attractive, non-dilutive terms of the loan as beneficial for upcoming data release and trial initiation, crucial for the company's oncolytic viral immunotherapy programs.
Candel Therapeutics, Inc. (Nasdaq: CADL) has appointed Francesca Barone, M.D., Ph.D., as its new Chief Scientific Officer. With over 20 years of expertise in immunology and drug development, Dr. Barone previously served as Candel's Vice President, Head of Research. She has substantial experience from her roles at Kintai Therapeutics and Senda Biosciences. Dr. Barone expressed optimism about the company's investigational immunotherapies aimed at treating cancer, emphasizing their unique ability to induce strong immune responses. This leadership change aims to enhance Candel's clinical development efforts.
Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company specializing in oncolytic viral immunotherapies, announced upcoming presentations at two virtual investor conferences in January 2022. Paul Peter Tak, CEO, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, with on-demand viewing starting at 7:00 am ET. He will also present live at the B. Riley Securities’ 2022 Oncology Conference on January 28, 2022, at 11:30 am ET. The company focuses on advancing cancer treatments through innovative engineered viruses.
Bionaut Labs and Candel Therapeutics have formed a strategic collaboration to advance preclinical development of remote-controlled microscale robots for targeted delivery of oncolytic viral immunotherapies to brain tumors. Utilizing Bionaut’s precision medicine technology, the partnership aims to enhance therapeutic efficacy for high-grade glioma patients. Both companies will retain rights to their platforms while working together towards clinical trials. Terms of the agreement remain undisclosed.
Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the Partnership for Accelerating Cancer Therapies (PACT) for a biomarker analysis in a phase 2 clinical trial targeting non-small cell lung cancer (NSCLC). The study will evaluate the efficacy of CAN-2409 combined with immune checkpoint inhibitors following inadequate responses to initial treatments. With three patient cohorts, the collaboration aims to identify early biological indicators of treatment response. This partnership enhances Candel's research credibility and aims to advance therapeutic options for cancer patients.
Candel Therapeutics (Nasdaq: CADL) presented encouraging data from its phase 1 trial of CAN-3110 at the SITC Annual Meeting. This oncolytic virus therapy showed significant T-cell infiltration and immune activation in patients with recurrent high-grade glioma. Preliminary data previously reported at ASCO indicated an overall survival of 11.7 months. The histological analysis confirmed persistence of viral antigens and a strong immune response, suggesting the potential of CAN-3110 to improve treatment outcomes for patients with this challenging cancer.
Candel Therapeutics (Nasdaq: CADL) reported its Q3 financial results, announcing a net loss of $16.2 million for the quarter, a substantial increase from $2.6 million in Q3 2020. Cash reserves as of September 30, 2021, stood at $88.4 million, bolstered by an IPO in August 2021. Research and development expenses surged to $5.3 million from $1.8 million year-over-year, attributed to increased clinical trial activities. The company remains on track to fund operations into Q2 2023, with several clinical presentations highlighting advancements in its oncolytic viral therapies, CAN-2409 and CAN-3110.
On November 2, 2021, Candel Therapeutics, Inc. (Nasdaq: CADL) announced that CEO Paul Peter Tak will speak at several investor conferences in November.
- Credit Suisse 30th Annual Healthcare Conference: Fireside Chat on November 8, 2021, at 11:20 am ET.
- BMO Biopharma Spotlight Series: Panel Discussion on November 8, 2021, at 12:45 pm ET.
- Jefferies London Healthcare Conference: Fireside Chat on November 17, 2021, at 1:00 pm GMT.
For more information and webcasts, visit Candel's website.
Candel Therapeutics (Nasdaq: CADL) announced its participation in key medical conferences, including the 13th International Oncolytic Virus Conference and the 26th Annual Meeting of the Society for Neuro-Oncology. Presentations will focus on their oncolytic viral immunotherapies, CAN-3110 and CAN-2409, with insights into their trial data. Notably, CAN-2409 targets high-grade gliomas and shows promise in combination therapies. The events are scheduled for November 5, 6, and 19, 2021, with additional details available on Candel's website.
Candel Therapeutics (Nasdaq: CADL) presented tolerability data from its phase 3 clinical trial of CAN-2409 for localized prostate cancer at the 28th Annual Prostate Cancer Foundation Scientific Retreat on October 28, 2021. The trial involved 745 patients, with over 2,000 injection procedures performed. Results showed 65% of patients found transperineal injections equally or better tolerated than biopsies, while 89% reported the same for transrectal injections. Overall, 100% felt positive about their participation. This supports the treatment's promise, potentially improving outcomes while reducing the need for long-term androgen deprivation therapy.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
